Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Dishman Carbogen AmicsNSE:DCAL -2.46%74 EV-to-EBITDA is 8.09 as of Aug. 11, 2026, which is 7% below its 10-year median of 8.69. GuruFocus rates NSE:DCAL with a GF Score™ of 74/100 and a GF Value™ of ₹239.14 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 402 Biotechnology companies, Dishman Carbogen Amics ranks better than 58.71% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Dishman Carbogen Amics's enterprise value is ₹49,951 Mil.
Dishman Carbogen Amics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was ₹6,178 Mil. Therefore, Dishman Carbogen Amics's EV-to-EBITDA for today is 8.09.
The historical rank and industry rank for Dishman Carbogen Amics's EV-to-EBITDA or its related term are showing as below:
NSE:DCAL'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 1.34 Med: 8.69 Max: 22.82
Current: 8.09
During the past 13 years, the highest EV-to-EBITDA of Dishman Carbogen Amics was 22.82. The lowest was 1.34. And the median was 8.69.
NSE:DCAL's EV-to-EBITDA is ranked better than 58.71% of 402
companies
in the Biotechnology industry
Industry Median: 13.3
vs NSE:DCAL: 8.09
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Dishman Carbogen Amics's PE Ratio (TTM) for today is calculated as:
Dishman Carbogen Amics's share price for today is ₹188.30.
Dishman Carbogen Amics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹6.210.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:DCAL vs VRTX, REGN, RVMD: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Dishman Carbogen Amics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dishman Carbogen Amics EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Dishman Carbogen Amics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Dishman Carbogen Amics's EV-to-EBITDA falls into.
Dishman Carbogen Amics's current Enterprise Value is ₹49,951 Mil.
Dishman Carbogen Amics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹6,178 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dishman Carbogen Amics (NSE:DCAL) has a EV-to-EBITDA of 8.09 as of Aug. 11, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Dishman Carbogen Amics. This is near median its historical median of 8.69. Over the past decade, Dishman Carbogen Amics' EV-to-EBITDA has ranged from 1.34 to 22.82. According to the industry distribution chart, Dishman Carbogen Amics ranks #166 out of 402 companies in the Biotechnology industry, placing it in the top 41.3%.
Is Dishman Carbogen Amics' EV-to-EBITDA too high?
Dishman Carbogen Amics' current EV-to-EBITDA of 8.09 is near median its 10-year median of 8.69. Over the past 10 years, this metric has ranged from a low of 1.34 to a high of 22.82. The Biotechnology industry median EV-to-EBITDA is 13.30. Dishman Carbogen Amics' value of 8.09 is 39.2% below this industry median. Based on the distribution chart, Dishman Carbogen Amics ranks #166 out of 402 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Dishman Carbogen Amics has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Dishman Carbogen Amics' EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Dishman Carbogen Amics ranks #166 out of 402 companies for EV-to-EBITDA. This puts Dishman Carbogen Amics in the upper half of its industry. The industry median EV-to-EBITDA is 13.30. Dishman Carbogen Amics' value of 8.09 is 39.2% below this benchmark. Historically, Dishman Carbogen Amics' own EV-to-EBITDA has ranged from 1.34 to 22.82 over the past decade. While the company's 10-year median is 8.69 vs. the industry median of 13.30, Dishman Carbogen Amics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.30, based on 402 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dishman Carbogen Amics's current EV-to-EBITDA of 8.09 is 39.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Dishman Carbogen Amics. For the Biotechnology industry, the median EV-to-EBITDA is 13.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dishman Carbogen Amics's current EV-to-EBITDA is 8.09, which is near median its own 10-year median of 8.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dishman Carbogen Amics stock overvalued right now?
Based on GuruFocus' analysis, Dishman Carbogen Amics (NSE:DCAL) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹239.14, compared to a current price of ₹188.30 — trading 21.3% below its estimated fair value. The current EV-to-EBITDA is 8.09, which is near median its 10-year median of 8.69 and 39.2% below the Biotechnology industry median of 13.30. Dishman Carbogen Amics' overall GF Score™ is 74/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Dishman Carbogen Amics (NSE:DCAL), the current EV-to-EBITDA is 8.09 as of Aug. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dishman Carbogen Amics (NSE:DCAL) Overvalued in 2026?
Based on GuruFocus' analysis, Dishman Carbogen Amics stock appears to be undervalued.
The current stock price of ₹188.30 is trading 21.3% below its estimated GF Value™ of ₹239.14.
GuruFocus considers Dishman Carbogen Amics to be Modestly Undervalued.
Key valuation signals for NSE:DCAL:
EV-to-EBITDA: 8.09 (near median its 10-year median of 8.69)
GF Value™: ₹239.14 vs. price of ₹188.30 (21.3% below fair value)
Industry Position: 39.2% below the Biotechnology median (#166 of 402)
No single metric tells the full story. See the NSE:DCAL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dishman Carbogen Amics Ltd is a biotechnology company that provides contract research and manufacturing services for pharmaceutical companies. It manufactures bulk drugs, specialty chemicals, and outsourced goods. Additionally, the company produces vitamins, such as vitamin D2 and vitamin D3, reagents, antiseptics and disinfectants, transfer catalysts, personal-care ingredients, pharma intermediates, and ammonium and phosphonium high-purity solid Quats. The business generates the vast majority of its revenue in India.
74GF Score
Get the complete analysis for NSE:DCAL
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:DCAL has been successfully added to your 
